



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. SERIAL NO. : 10/729,704  
APPLICANTS : Guenzler-Pukall, et al.  
FILING DATE : 4 December 2003  
GROUP ART UNIT : 1654  
EXAMINER : Roy R. Teller  
DOCKET NO. : FP0602.1 US  
TITLE : TREATMENT OF DIABETES

---

Commissioner for Patents  
PO Box 1450  
Alexandria VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. 1.97(b)**

Sir:

Pursuant to 37 C.F.R. 1.56, 1.97, and 1.98, Applicant wishes to call to the attention of the Examiner the enclosed "Information Disclosure Statement By Applicant" (Forms PTO/SB/08a and PTO/SB/08b). Applicant reserves the right to antedate any reference in accordance with standard procedure.

The art listed on the attached forms PTO/SB/08a and PTO/SB/08b was first cited in a partial European Search Report established in corresponding European Patent Application No. 10188906.1. Copies of the non-patent citations and the partial European Search Report are provided with this communication. In accordance with 37 C.F.R. 1.98(d), a copy of any patent, publication, pending U.S. application, or other information are not provided with this communication.

Citation of the document is not to be construed as an admission that the document are necessarily prior art with respect to the present application. In addition, this submission is understood to complement the results of the Examiner's own independent search. Citation of the document shall not be construed as a representation that a search has been made or that the cited item is inclusive of all the relevant and material citations that may be available publicly. Any NCBI or other report included on the attached list may not have an accurate date for prior art purposes. The document may have markings thereon. No significance is meant to be attached to the markings.


Applicant respectfully requests that the cited document be considered by the Examiner and that initialed copies of forms PTO/SB/08a and PTO/SB/08b be returned to Applicant.

Applicants believe that no fee is due in this submission since the Information Disclosure Statement is being filed within three months of receipt of the partial European Search Report. However, should the Commissioner determine that a fee is due, authorization is hereby given to charge the total of any such fee due to Deposit Account No. 50-0811, referencing Docket No. FP0602.1 US.

Please call Applicant's representative at 415-978-1748 with any questions regarding this communication or the above-identified application.

Respectfully submitted,

Date: 3-11-2011

By:   
Paul Borchardt, Ph.D.  
Reg. No. 53,999

FibroGen, Inc.  
409 Illinois Street  
San Francisco, CA 94158  
Main: 415-978-1200  
Direct: 415-978-1748  
Facsimile: 415-978-1917  
[pborchardt@fibrogen.com](mailto:pborchardt@fibrogen.com)